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Trends and Costs of External Electrical Bone 
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Study Design: Retrospective review.
Purpose: To identify the trends in stimulator use, pair those trends with various grafting materials, and determine the influence of 
stimulators on the risk of revision surgery.
Overview of Literature: A large number of studies has reported beneficial effects of electromagnetic energy in healing long bone 
fractures. However, there are few clinical studies regarding the use of electrical stimulators in spinal fusion.
Methods: We used insurance billing codes to identify patients with lumbar disc degeneration who underwent anterior lumbar in-
terbody fusion (ALIF). Comparisons between patients who did and did not receive electrical stimulators following surgery were per-
formed using logistic regression analysis, chi-square test, and odds ratio (OR) analysis.
Results: Approximately 19% of the patients (495/2,613) received external stimulators following ALIF surgery. There was a slight in-
crease in stimulator use from 2008 to 2014 (multi-level R 2=0.08, single-level R 2=0.05). Patients who underwent multi-level procedures 
were more likely to receive stimulators than patients who underwent single-level procedures (p<0.05; OR, 3.72; 95% confidence 
interval, 3.02–4.57). Grafting options associated with most frequent stimulator use were bone marrow aspirates (BMA) plus autograft 
or allograft for single-level and allograft alone for multi-level procedures. In both cohorts, patients treated with bone morphogenetic 
proteins were least likely to receive electrical stimulators (p<0.05). Patients who received stimulation generally had higher reimburse-
ments. Concurrent posterior lumbar fusion (PLF) (ALIF+PLF) increased the likelihood of receiving stimulators (p<0.05). Patients who 
received electrical stimulators had similar revision rates as those who did not receive stimulation (p>0.05), except those in the multi-
level ALIF+PLF cohort, wherein the patients who underwent stimulation had higher rates of revision surgery.
Conclusions: Concurrent PLF or multi-level procedures increased patients’ likelihood of receiving stimulators, however, the presence 
of comorbidities did not. Patients who received BMA plus autograft or allograft were more likely to receive stimulation. Patients with 
and without bone stimulators had similar rates of revision surgery.
Keywords: Lumbar spine; Intervertebral disc degeneration; Stimulators; Grafts; Costs and cost analysis
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Introduction
Considerable evidence supports the use of electromagnet-
ic energy to help heal long bone fractures. However, few 
clinical studies have examined electrical stimulators with 
spinal fusion, especially with anterior lumbar interbody 
fusion (ALIF). With the aging population, the prevalence 
of spinal degenerative conditions and fusion surgeries to 
address such pathologies has increased [1,2]. Fusion suc-
cess is associated with patient outcomes; therefore, the 
methods to improve fusion rates may provide clinical and 
financial advantages [3-6].
In 1974, Dwyer and Wickham [7] published results 
demonstrating the benefit of direct current stimulation 
(DCS) for lumbar spinal fusion. Thereafter, Kane [8] con-
ducted a randomized prospective trial wherein DCS re-
sulted in higher fusion success rates than non-stimulated 
patients, even among high-risk patients. Patients are con-
sidered to be at high-risk if they were smokers, morbidly 
obese, diabetic, had spondylolisthesis, or were undergoing 
a reoperation or multi-level fusion [7-9].
 Non-invasive, external alternatives to DCS include 
pulsed electromagnetic field stimulation (PEMFS) and 
capacitive coupled electrical stimulation [10]. These 
techniques are advantageous over DCS in terms of lower 
operating times, blood loss, hardware removal, and infec-
tion potential. In 1990, Mooney [11] demonstrated more 
favorable fusion outcomes among compliant patients with 
external stimulators; however, they did not stratify their 
results based on the anterior and posterior approaches. 
Moreover, other animal studies have not corroborated 
these results [9,12]. This suggests that the benefits of elec-
trical stimulation depend on factors, such as regions of 
the spine or surgical approach or that improvements in 
surgical technique since the Mooney study have mitigated 
the potential benefit of the stimulators.
Recent basic science studies have proposed that external 
electromagnetic bone stimulators work via the upregula-
tion of bone growth factors, including bone morphoge-
netic proteins (BMPs) [13]. Some grafting materials are 
employed for similar purposes. ALIFs can be supple-
mented with autograft, allograft, recombinant-human 
BMP, bone marrow aspirate (BMA), or a combination of 
these. Iliac crest bone graft (ICBG) remains the ‘gold stan-
dard’ of grafting materials because of its minimal immune 
response and optimal osteogenic, osteoconductive, and 
osteoinductive properties. However, it is found to have 
high donor site morbidity, greater neurovascular injury, 
and increased operation time. Allograft, BMP, and BMAs 
are alternatives that are less invasive alternatives; however, 
they lack some of bone growth qualities that make ICBG 
ideal [14,15].
This study aimed to identify the trends in bone stimula-
tor usage, determine the prevalence of different grafting 
materials used for ALIF procedures with and without 
stimulators, as well as compare the incidence of revision 
surgery between patients who did and did not receive 
bone stimulation. We also aimed to assess the costs asso-
ciated with these procedures.
Materials and Methods
We used the PearlDiver Patient Record Database (Pearl-
Diver Technologies Inc., Warsaw, IN, USA; http://www.
pearldiverinc.com/) to follow up patients longitudinally 
for 1 year after their initial ALIF or ALIF+posterior lum-
bar fusion (PLF) surgery (ALIF+PLF=ALIF with concom-
itant PLF). Patient groups were divided as per the Current 
Procedural Terminology and the International Classifica-
tion of Diseases, 9th edition insurance billing codes. We 
focused on patients within the database who were insured 
through Humana (Louisville, KY, USA) because the Hu-
mana population involved a wide age range and included 
nearly 20 million patients from the beginning of 2007 to 
the third quarter of 2015.
All the patients included in this study had lumbar disc 
degeneration within a year prior to their index procedure. 
Further, no patient had fractures or cancers of the spine.
Surgery type was classified as single- versus multi-level 
and ALIF-only versus ALIF+PLF. Throughout this paper, 
unless otherwise specified, ‘ALIF’ includes all patients 
who underwent only ALIF or ALIF+PLF procedure. To 
stratify patients based on the grafting material, we identi-
fied patients billed for autograft, allograft, autograft and 
allograft, BMA, BMP, BMA+graft, and BMP+graft on 
the day of their index procedure.
We determined how many patients from each group 
were billed for electrical stimulators within 3 months of 
their index ALIF procedure. Thereafter, we compared the 
number of patients who underwent a second surgery be-
tween those who did and did not receive stimulation. Any 
ALIF, PLF, PLIF, discectomy, or laminectomy performed 
within a year of the index ALIF was considered a revision 
surgery.
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Statistical analyses were performed using chi-square 
analysis or R software (https://www.r-project.org/) for 
logistic regression. Significance was set at p<0.05. Odds 
ratio (OR) data were included with a 95% confidence 
interval (CI) where comparisons could be made in a 2×2 
contingency table.
The analyzed cost data indicate the average amount 
Humana reimbursed to physicians and facilities for all the 
costs incurred by the patient for their care over a one-day 
or a 1-year period from the date of surgery. Due to the 
data being de-identified and commercially available, no 
Institutional Review Board approval was needed.
Results
In the Humana subset of the PearlDiver database, between 
January 2007 and December 2014, 2,613 patients un-
derwent ALIF within a year of lumbar disc degeneration 
diagnosis. Of those patients, 1,520 (58.2%) were billed for 
single-level and 1,093 (41.8%) were billed for multi-level 
ALIF. The ALIF was combined with a PLF (ALIF+PLF) in 
42.4% of the single-level fusion patients and 49.6% of the 
multi-level fusion patients. ALIF+PLF patients underwent 
multi-level fusions more commonly than the ALIF-only 
patients (X2 p<0.05; OR, 1.590; 95% CI, 1.36–1.86).
After adjusting for the number of patients included in 
the database in each age group, single-level ALIF proce-
dures were found to be most frequent in patients aged 
45–49 years, while multi-level ALIF procedures were most 
frequent among patients aged 60–64 years (Fig. 1). Men 
were slightly more likely to undergo single-level ALIF, 
while women were slightly more likely to undergo multi-
level ALIF (p<0.05 for ALIF-only and ALIF+PLF).
The number of patients who underwent single- or 
multi-level ALIF procedure increased from 2008 to 2014 
even after considering the rise in the population within 
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Fig. 1. Age trends among patients undergoing ALIF. Single-ALIFs are performed on a slightly younger population. ALIF, anterior 
lumbar interbody fusion.
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Fig. 2. An increase in the use of single- and multi-level ALIFs from 
2008 to 2014, both with and without concurrent PLF procedures. ALIF, 
anterior lumbar interbody fusion; PLF, posterior lumbar fusion.
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Fig. 3. Percentage of patients who did not receive stimulators follow-
ing a single- or multi-level ALIF-only procedure. A minor decrease in 
the percentage of patients who did not receive stimulation indicates 
a minor increase in patients receiving stimulators following ALIF-only 
procedures. ALIF, anterior lumbar interbody fusion.
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the database (Fig. 2). The percentage of patients who 
received stimulators increased only slightly from 2008 
to 2014 (Figs. 3, 4). Comorbidities, such as smoking, dia-
betes, and obesity that were diagnosed on the day of the 
index procedure did not significantly influence the likeli-
hood of stimulator use (p>0.05 for all).
Total 495 patients (18.9%) were billed for an external 
stimulator within 3 months of their ALIF. No patient was 
billed for an internal stimulator. More patients with multi-
level ALIFs (334/1,093, 30.6%) underwent stimulation 
than those with single-level ALIFs (161/1,520, 10.6%) (X2 
p<0.05; OR, 3.72; 95% CI, 3.02–4.57). Similar trends were 
observed after specifying if the ALIF was performed in 
conjunction with a PLF (X2 p<0.05; ALIF+PLF: 95% OR, 
1.48; 95% CI, 1.15–1.89; ALIF-only: OR, 4.59; 95% CI, 
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Fig. 4. Percentage of patients who did not receive stimulators follow-
ing a single- or multi-level ALIF+PLF procedures. A minor decrease in 
the percentage of patients who did not receive stimulation indicates a 
minor increase in those receiving stimulators following ALIF+PLF pro-
cedures. ALIF, anterior lumbar interbody fusion; PLF, posterior lumbar 
fusion.
Table 1. Total number of patients who receive single-level, multi-level, or any ALIF, and the number and percent of those patients who were billed 
for an external stimulator within 3 months of that procedure
Variable Total patients Stimulated patients (%) Significant difference
ALIF-only p<0.05
Single-level ALIF-only 933 76 (8.1)
Multi-level ALIF-only 494 143 (28.9)
ALIF 1,427 219 (15.3)
ALIF+PLF p<0.05
Single-level ALIF+PLF 644 101 (15.7)
Multi-level ALIF+PLF 542 174 (32.1)
ALIF 1,186 275 (23.1)
General ALIF p<0.05
Single-level ALIF 1,520 161 (10.6)
Multi-level ALIF 1,093 334 (30.6)
ALIF 2,613 495 (18.9)
ALIF, anterior lumbar interbody fusion; PLF, posterior lumbar fusion.
Multi-level ALIF patients were significantly more likely to be billed for stimulators for ALIF+PLF and ALIF-only patients (and ALIF in general) (p<0.05).
Table 2. Correlation of stimulator use with revision surgery
Variable Stimulated Revision (%) Non-stimulated Revision (%) p-value
Single-level
ALIF-only 69 <11 799 54 (6.8) 0.3442
ALIF+PLF 91 <11 522 21 (4.0) 0.2814
Multi-level
ALIF-only 125 11 (8.8) 326 29 (8.9) 0.3013
ALIF+PLF 156 17 (10.9) 342 13 (3.8) 0.0005
In three of four patient groups, stimulators did not appear to significantly affect the likelihood of undergoing revision surgery, and in four of four 
groups did not reduce the likelihood of revision surgery. Patients who received stimulators after a primary multi-level ALIF+PLF were more likely to 
undergo a revision surgery compared to patients who did not receive stimulators.
ALIF, anterior lumbar interbody fusion; PLF, posterior lumbar fusion.
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3.39–6.23) (Table 1). Single-level ALIF+PLF patients were 
nearly twice as likely to receive stimulators than single-
level ALIF-only patients (X2 p<0.05; OR, 2.10; 95% CI, 
1.53–2.88). Multi-level ALIF+PLF patients were more 
likely to receive stimulators than multi-level ALIF-only 
patients; however, the result was statistically insignificant 
(X2 p=0.27; OR, 1.161; 95% CI, 0.890–1.513).
In three of the four patient groups: single-level ALIF-
only, single-level ALIF+PLF, and multi-level ALIF-only, 
stimulators had no significant effect on the likelihood of 
revision surgery (X2 p>0.05). Patients who received stimu-
lators following a multi-level ALIF+PLF were more likely 
to require revision surgery (X2 p<0.05; OR, 3.10; 95% CI, 
1.46–6.55) (Table 2).
BMP was the most common grafting option (single-
level 16.5% and multi-level 14.0%), and BMA+graft was 
the least common (single-level 3.3% and multi-level 3.3%). 
The number of patients who received stimulators in each 
of the seven different grafting subgroups is presented in 
Table 3. Among the single-level ALIF cohort, patients who 
received BMA+graft or allograft+autograft had a higher 
likelihood of receiving stimulators (p<0.05). In the multi-
level cohort, patients who received allograft, autograft, 
BMA+graft, or BMP+graft had a higher likelihood of 
receiving stimulators (p<0.05). BMP patients consistently 
had a lower likelihood of receiving stimulators (p<0.05) 
(Table 3, Fig. 5).
Patients who underwent ALIF+PLF procedures in-
curred higher costs than those who underwent ALIF-
only procedures. Further, in patients with and without 
Table 3. Number of patients who received each type of grafting option, and the percentage of those patients who also received stimulators
Variable
Single-level Multi-level
Total Stimulated patients (%) Total Stimulated patients (%)
Autograft 104   13 (12.5) 100 40 (40.0)
Allograft 146 13 (8.9) 93 30 (32.3)
BMA 94   <11 (<10.6) 40 13 (32.5)
BMP 251 <11 (<4.0) 153 39 (25.5)
Autograft and allograft 60   <11 (<16.7) 47 15 (31.9)
BMA+graft 50   20 (40.0) 36 14 (38.9)
BMP+graft 114 <11 (<8.8) 61 23 (37.7)
BMA, bone marrow aspirate; BMP, bone morphogenetic protein.
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Fig. 5. Percentage of patients billed for an external stimulator after an ALIF with a specific grafting option. BMA, bone marrow as-
pirate; BMP, bone morphogenetic protein.
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stimulators, the difference was more pronounced among 
those who received stimulators. Patients who eventually 
received stimulators incurred a higher cost than those 
who did not undergo stimulation, both on the day of the 
surgery and over a 1-year period. Generally, over a year-
long period (excluding the day of surgery), patients who 
received stimulators within 3 months of ALIF incurred a 
39% and 11% higher cost than those who did not receive 
stimulators for single- and multi-level procedures, respec-
tively. Notable exceptions were patients grafted with BMA 
and allograft or autograft. BMA+graft patients who did 
not receive stimulators had, on an average, $15,937 more 
health-related costs after a year than similarly grafted pa-
tients who received stimulation.
Discussion
1. General trends in stimulator usage
The present data demonstrated variable usage of stimula-
tors. Stimulators were used with a wide range of grafting 
materials and were not significantly associated with co-
morbidities, such as diabetes, smoking, and obesity, at the 
time of surgery. However, stimulators were consistently 
used more commonly for patients undergoing more com-
plex procedures.
Previous studies recommended the use of electrical 
stimulators to aid fusion for ‘high-risk’ patients, including 
patients undergoing revision surgery or multi-level fusion 
[8,9,11]. Our data were consistent with these recommen-
dations in that stimulators were more commonly used for 
patients undergoing multi-level fusion. Moreover, stimu-
lators were used more frequently for patients undergoing 
ALIF+PLF rather than ALIF-only. We believe that patients 
undergoing ALIF+PLF represented more severe cases 
than those undergoing ALIF-only. Patients who received 
concurrent PLFs were more likely to receive stimulators 
for single- and multi-level procedures; however, the result 
was only significant for single-level procedures.
In previous studies, patients who were diabetic, obese, 
and smoked were also considered ‘high-risk’ candidates 
who could benefit from the use of stimulators [8,9, 
11,16,17]. Although two of these studies focused on inter-
nal stimulators (DCS), Mooney [11] in 1990 reported that 
external stimulation (PEMFS) could lower the adverse 
effects of smoking on fusion success. While our data did 
not show any significant differences in stimulator usage in 
patients with and without these comorbidities, it would be 
worthwhile to evaluate if external stimulators may benefit 
these patients in future studies.
2.  Trends in grafting materials used in conjunction with 
stimulators
Thus far, studies that have analyzed electrical stimulators 
have only focused on patients treated with autograft or 
allograft. In 1990, Mooney [11] found similar fusion suc-
cess rates for patients treated with autograft or allograft. 
We found that allograft, autograft, or a combination of 
these two were among the popular grafting options that 
established the use of stimulators; however, patients 
treated with BMA+autograft or allograft were consistently 
more likely to receive electrical stimulators. Single-level 
BMA+graft patients were substantially more likely to 
receive stimulators than patients who underwent single-
level procedures. In contrast, multi-level BMP patients 
were substantially less likely to receive stimulators than 
patients who underwent multi-level procedures. However, 
the most consistent trend among the different grafting 
options was that patients who underwent multi-level 
procedures were prescribed stimulators more commonly 
than those who underwent single-level procedures. Other 
grafting options, when compared to the general popula-
tion of ALIF patients, did not stand out in terms of having 
a clear influence on whether or not stimulators were used. 
While these data validate the previous discussion regard-
ing patients who undergo multi-level procedures being 
more likely to receive stimulation, it also highlights the 
diverse population of patients who receive stimulation.
As per previous reports, patients who received BMA 
and autograft or allograft were prescribed stimulators 
more frequently [13,18-20]. BMA is believed to possess 
osteogenicity and osteoinductivity [19]. External electrical 
stimulators work on already differentiated cells; there-
fore, their use may enhance the osteogenic properties of 
BMA [13]. Autograft and allograft have osteoconductiv-
ity; therefore, BMA, in conjunction with autograft or al-
lograft, may contain all the following three qualities of an 
ideal bone graft: osteoconductivity, osteoinductivity, and 
osteogenicity [13,20].
3. Costs
From an economic perspective, patients who received 
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stimulators were associated with higher costs. On an aver-
age, the total cost per patient on the day of surgery was 
27% higher for single-level ALIF-only patients who would 
eventually receive stimulation than for those who would 
not. Most external stimulators are administered after the 
day of the surgery; moreover, stimulated patients were 
usually associated with higher same-day reimbursements 
than non-stimulated patients; therefore, we used this as a 
rationale to support the notion that patients who received 
stimulators generally represented more complex and/or 
challenging cases that required more time and resources.
Patients who received stimulators were also associated 
with greater costs over a 1-year period (excluding the day 
of the surgery), except for multi-level ALIF patients. The 
cost for multi-level ALIF patients treated with BMA+graft 
who received stimulators, was on an average $15,937 
lower throughout the year than that for those treated with 
BMA+graft who did not receive stimulators. However, in 
this subgroup, the stimulated patients also had lower costs 
on the day of the surgery than those who did not receive 
stimulators, potentially indicating less complex cases to 
begin with. However, this is an interesting result, consid-
ering that stimulators were more commonly for patients 
in the BMA+graft subgroup. Future studies should seek to 
clarify if stimulators affect the postoperative complication 
rates or if their effect is minimal compared to the underly-
ing complexity of the diagnosis.
4. Revision surgery
Although Mooney [11] demonstrated that external stimu-
lators could improve the rates of fusion success in 1990, 
to our knowledge, no recent data are available that clearly 
demonstrate the benefit of stimulator use. A recent pro-
spective study by Rogozinski et al. [21] in 2009 showed 
that DCS did not benefit fusion success in the elderly (age 
>60 years) lumbar fusion patients; this was contradictory 
to the findings of the 1988 study by Kane et al. [8] that 
showed that DCS improved fusion success rates [1]. Al-
though internal stimulators work differently and are used 
for different procedures than external stimulators, the 
contrasting results of these two studies may indicate that 
improvements in modern surgical technique have miti-
gated the potential benefit of stimulators.
In large-database studies, such as the present one, the 
rates of revision surgery are an imperfect proxy for the 
estimated clinical outcomes of an index procedure. How-
ever, considering their invasiveness, financial burden, 
and potential for further complications, revision surger-
ies are important clinical outcomes that physicians and 
patients attempt to avoid. We found that in three of the 
four patient groups (single-level ALIF-only, single-level 
ALIF+PLF, and multi-level ALIF-only), the use of stimu-
lators following the index procedure did not significantly 
affect the likelihood of revision surgery. Among multi-
level ALIF+PLF patients, those who underwent stimula-
tion exhibited a significantly higher likelihood of revision 
surgery. We considered this as more evidence of the fact 
that those patients had more complicated underlying 
diagnoses. The null effects of stimulators on the revision 
rates among the other cohorts were another interesting 
result.
Patients may have undergone revision surgery due to 
several reasons beyond the scope of what we were able to 
determine using insurance billing codes. Our privacy con-
tract with PearlDiver Inc. prevented us from performing a 
more stratified analysis of certain patient groups, such as 
smokers, because even with a large database, the sample 
size was inadequate for such analyses. However, while 
there might have been some patient groups for whom 
stimulators were beneficial, the data suggested that over-
all, stimulators overall did not exert a strong influence on 
the rates of revision surgery.
This study aimed to report, based on a large-scale per-
spective research, the trends that have influenced stimula-
tor usage. It is clear that patients who undergo ALIF are 
diverse, and the factors that influence the use of stimula-
tors also vary; therefore, we identified that stimulators 
were prescribed for more complex and challenging cases 
and were more frequently used with BMA plus autograft 
or allograft. Our data did not show any positive effect of 
stimulator use on the rates of revision surgery; therefore, 
future studies should explore specific patient populations 
that may benefit from stimulator use.
Conclusions
The present data indicated that physicians tend to pre-
scribe stimulators for more complex and challenging 
cases, such as multi-level fusion or ALIF+PLF. Moreover, 
we demonstrated that stimulators were more commonly 
used in cases where the grafting material was BMA plus 
autograft or allograft. However, there was no patient 
group wherein the frequency of external stimulator usage 
Anthony D’Oro et al.980 Asian Spine J 2018;12(6):973-980
suggested a clear standard of care.
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